These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 3412589)

  • 1. Does levodopa aggravate Parkinson's disease?
    Blin J; Bonnet AM; Agid Y
    Neurology; 1988 Sep; 38(9):1410-6. PubMed ID: 3412589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease].
    Baronti F; Ruggieri S; Mouradian MM; Bonamartini A; Bocciarelli P; De Pandis MF; Chase TN; Agnoli A
    Riv Neurol; 1991; 61(6):210-4. PubMed ID: 1813972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease.
    Pourcher E; Bonnet AM; Kefalos J; Dubois B; Agid Y
    Mov Disord; 1989; 4(3):195-201. PubMed ID: 2779590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of dyskinesias in Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Fabbrini G; Juncos JL; Chase TN
    Ann Neurol; 1989 May; 25(5):523-6. PubMed ID: 2774496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromocriptine combined with levodopa in Parkinson's disease.
    Gauthier G; Martins da Silva A
    Eur Neurol; 1982; 21(4):217-26. PubMed ID: 7117308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of treatment with levodopa on Parkinson's disease.
    Shaw KM; Lees AJ; Stern GM
    Q J Med; 1980; 49(195):283-93. PubMed ID: 7465763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
    Papathanou M; van der Laan R; Jenner P; Rose S; McCreary AC
    Mov Disord; 2013 Jul; 28(8):1072-9. PubMed ID: 23125107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-tryptophan supplementation in Parkinson's disease.
    Sandyk R; Fisher H
    Int J Neurosci; 1989 Apr; 45(3-4):215-9. PubMed ID: 2744962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
    Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
    Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.
    Sweet RD; McDowell FH
    Ann Intern Med; 1975 Oct; 83(4):456-63. PubMed ID: 1166978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations.
    Kempster PA; Gibb WR; Stern GM; Lees AJ
    J Neurol Neurosurg Psychiatry; 1989 Jan; 52(1):72-6. PubMed ID: 2709038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution and origin of motor complications in Parkinson's disease.
    Obeso JA; Rodriguez-Oroz MC; Chana P; Lera G; Rodriguez M; Olanow CW
    Neurology; 2000; 55(11 Suppl 4):S13-20; discussion S21-3. PubMed ID: 11147505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease.
    Barbeau A; Roy M
    Neurology; 1976 May; 26(5):399-404. PubMed ID: 944392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-dopa long-term treatment in Parkinson's disease: age-related side effects.
    Pederzoli M; Girotti F; Scigliano G; Aiello G; Carella F; Caraceni T
    Neurology; 1983 Nov; 33(11):1518-22. PubMed ID: 6415513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot?
    Vidailhet M; Bonnet AM; Marconi R; Gouider-Khouja N; Agid Y
    Neurology; 1994 Sep; 44(9):1613-6. PubMed ID: 7936284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2000; 2001(3):CD001517. PubMed ID: 10908504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease.
    Cedarbaum JM; Gandy SE; McDowell FH
    Neurology; 1991 May; 41(5):622-9. PubMed ID: 2027475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of clinical response and plasma dopa levels in Parkinson's disease.
    Tolosa ES; Martin WE; Cohen HP; Jacobson RL
    Neurology; 1975 Feb; 25(2):177-83. PubMed ID: 1167646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.